Medicare Enrolled
Dr. Alexander Ostrovsky, MD
Hematology & Oncology · Langhorne, PA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Ostrovsky from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Ostrovsky?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Ostrovsky
Dr. Alexander Ostrovsky is a hematology & oncology specialist in Langhorne, PA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Ostrovsky performed 57,323 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Ostrovsky received a total of $8,921 from 77 pharmaceutical and/or device companies across 441 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Ostrovsky is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years of NPI registration
▲ Top 11% volume in PA
$8,921 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗57,323
Medicare services
Top 11% in PA for hematology & oncology
Not available
Unique patients (not deduplicated)
$9
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
26,995 | $2 | $21 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
10,650 | $0 | $6 |
| Denosumab injection (Prolia/Xgeva) | 5,760 | $17 | $68 |
| Iron infusion (Monoferric) | 5,561 | $16 | $73 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
1,354 | $8 | $35 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,330 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,110 | $1 | $122 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
1,025 | $8 | $19 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
723 | $71 | $148 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
428 | $13 | $105 |
| Pegfilgrastim-apgf injection An injection of pegfilgrastim-apgf, a biosimilar medication. The dose specified is 0.5 mg. |
372 | $91 | $879 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
320 | $111 | $686 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
305 | $12 | $93 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
248 | $104 | $224 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
176 | $66 | $157 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
113 | $54 | $304 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
111 | $24 | $152 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
101 | $22 | $156 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
100 | $144 | $412 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
85 | $99 | $232 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
75 | $1 | $7 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
65 | $10 | $73 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
63 | $55 | $334 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
60 | $85 | $220 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
42 | $1 | $9 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
42 | $2 | $19 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
36 | $25 | $249 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
22 | $130 | $347 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
21 | $144 | $301 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
18 | $1 | $19 |
| New patient office visit, complex (60-74 min) | 12 | $186 | $440 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
10.9% high complexity
82.2% medium
6.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$8,921
Total received (2018-2024)
Avg $1,274/year across 7 years
Top 24% in PA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
77
Companies
441
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,155
2023
$1,886
2022
$1,814
2021
$660
2020
$183
2019
$1,055
2018
$1,167
Payments by company (2024)
ABBVIE INC.
$155
Daiichi Sankyo Inc.
$139
Novartis Pharmaceuticals Corporation
$129
Eisai Inc.
$124
E.R. Squibb & Sons, L.L.C.
$113
Janssen Biotech, Inc.
$104
Astellas Pharma US Inc
$103
Merck Sharp & Dohme LLC
$101
AstraZeneca Pharmaceuticals LP
$96
Gilead Sciences, Inc.
$83
PFIZER INC.
$78
GENZYME CORPORATION
$68
Incyte Corporation
$67
Mirati Therapeutics, Inc.
$56
Stemline Therapeutics Inc.
$55
Genentech USA, Inc.
$46
Bayer Healthcare Pharmaceuticals Inc.
$45
JAZZ PHARMACEUTICALS INC.
$44
Celgene Corporation
$43
ARRAY BIOPHARMA INC
$41
Acrotech Biopharma Inc.
$40
SOBI, INC
$40
GlaxoSmithKline, LLC.
$39
RECORDATI_RARE_DISEASES_INC.
$38
Takeda Pharmaceuticals U.S.A., Inc.
$34
Karyopharm Therapeutics Inc.
$32
EMD Serono, Inc.
$26
Alexion Pharmaceuticals, Inc.
$26
Apellis Pharmaceuticals, Inc.
$25
Kite Pharma, Inc.
$25
PUMA BIOTECHNOLOGY, INC.
$23
CSL Behring
$21
BeiGene USA, Inc.
$19
Lilly USA, LLC
$19
SERVIER PHARMACEUTICALS LLC
$16
Rigel Pharmaceuticals, Inc.
$15
Secura Bio, Inc.
$15
ADC Therapeutics America, Inc.
$14
Top 3 companies account for 19.6% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$681
Janssen Biotech, Inc.
$649
Genentech USA, Inc.
$429
PFIZER INC.
$393
E.R. Squibb & Sons, L.L.C.
$354
AstraZeneca Pharmaceuticals LP
$353
Merck Sharp & Dohme Corporation
$331
Astellas Pharma US Inc
$328
ABBVIE INC.
$310
Merck Sharp & Dohme LLC
$306
Incyte Corporation
$305
Amgen Inc.
$289
Daiichi Sankyo Inc.
$263
Eisai Inc.
$199
GENZYME CORPORATION
$192
Pharmacyclics LLC, An AbbVie Company
$178
Gilead Sciences, Inc.
$149
Bayer Healthcare Pharmaceuticals Inc.
$146
Lilly USA, LLC
$141
Seagen Inc.
$135
Kite Pharma, Inc.
$133
Stemline Therapeutics Inc.
$119
GlaxoSmithKline, LLC.
$113
Celgene Corporation
$103
TerSera Therapeutics LLC
$101
TESARO, Inc.
$96
Mirati Therapeutics, Inc.
$95
AbbVie, Inc.
$86
Takeda Pharmaceuticals U.S.A., Inc.
$86
ARRAY BIOPHARMA INC
$86
JAZZ PHARMACEUTICALS INC.
$85
EISAI INC.
$85
Janssen Pharmaceuticals, Inc
$85
Boehringer Ingelheim Pharmaceuticals, Inc.
$81
EMD Serono, Inc.
$74
Apellis Pharmaceuticals, Inc.
$70
Acrotech Biopharma LLC
$64
Seattle Genetics, Inc.
$62
Myovant Sciences Inc.
$57
Acrotech Biopharma Inc.
$57
Pharmacyclics LLC, an AbbVie Company
$55
Rigel Pharmaceuticals, Inc.
$49
Foundation Medicine, Inc.
$49
Alexion Pharmaceuticals, Inc.
$48
Regeneron Healthcare Solutions, Inc.
$48
Mylan Institutional Inc.
$46
CSL Behring
$45
Sun Pharmaceutical Industries Inc.
$42
Puma Biotechnology, Inc.
$42
Helsinn Therapeutics (U.S.), Inc.
$40
SOBI, INC
$40
RECORDATI_RARE_DISEASES_INC.
$38
PUMA BIOTECHNOLOGY, INC.
$37
Bayer HealthCare Pharmaceuticals Inc.
$36
Karyopharm Therapeutics Inc.
$32
Exelixis Inc.
$31
G1 Therapeutics, Inc.
$23
Pharmacosmos Therapeutics Inc.
$22
Sumitomo Pharma America, Inc.
$22
INSYS Therapeutics Inc
$21
Ipsen Biopharmaceuticals, Inc
$20
MorphoSys, US Inc.
$20
SANOFI-AVENTIS U.S. LLC
$20
BeiGene USA, Inc.
$19
Heron Therapeutics, Inc.
$19
AbbVie Inc.
$19
Sobi, Inc
$17
Deciphera Pharmaceuticals Inc.
$17
Prometheus Laboratories Inc.
$16
Teva Pharmaceuticals USA, Inc.
$16
Agios Pharmaceuticals, Inc.
$16
SERVIER PHARMACEUTICALS LLC
$16
Secura Bio, Inc.
$15
Fortovia Therapeutics, Inc.
$15
ADC Therapeutics America, Inc.
$14
Dova Pharmaceuticals
$14
Taiho Oncology, Inc.
$11
Top 3 companies account for 19.7% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · AKYNZEO · AUGTYRO · Avastin · BELEODAQ · BENDEKA · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Blincyto · CABOMETYX · CALQUENCE · CARVYKTI · COPIKTRA · COSELA · CYRAMZA · DARZALEX · DOPTELET · Doptelet · ELAHERE · ELIQUIS · ELITEK · ELREXFIO · ENHERTU · ENJAYMO · EPKINLY · ERBITUX · ERLEADA · Empaveli · Enhertu · FOLOTYN · FULPHILA · GAZYVA · GILOTRIF · HEMADY · Halaven · Herceptin · Hizentra · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INQOVI · Imbruvica · JADENU · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LORBRENA · LUPRON DEPOT · LYNPARZA · Lenvima · Lunsumio · MEKINIST · MONJUVI · MONOFERRIC · MYLOTARG · NERLYNX · NINLARO · Neulasta · Nplate · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · Onivyde · Orserdu · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · PROMACTA · PYRUKYND · Perjeta · Polivy · Pomalyst · Proleukin · QINLOCK · REBLOZYL · Rezlidhia · SARCLISA · SCEMBLIX · SHINGRIX · SUSTOL · SUTENT · SYLVANT · SYNAGIS · SYNDROS · Stivarga · TABRECTA · TAGRISSO · TASIGNA · TECENTRIQ · TEPMETKO · TUKYSA · Tavalisse · Trodelvy · ULTOMIRIS · VENCLEXTA · VERZENIO · VONJO · VYXEOS · Venclexta · Vitrakvi · Voranigo · XALKORI · XARELTO · XPOVIO · XTANDI · Xofigo · Xospata · Xtandi · YONSA · Yescarta · ZEJULA · ZEPZELCA · ZOLADEX · Zoladex
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Hematology & oncology specialists in nearby ZIP areas
273
County median income
$111,951
Nearest hospital to ZIP centroid (approximate)
ST MARY MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Ostrovsky is a mixed practice specialist, with above-average Medicare volume (top 11% in PA), with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Ostrovsky experienced with darbepoetin injection (aranesp) for anemia?
Based on Medicare claims data, Dr. Ostrovsky performed 26,995 darbepoetin injection (aranesp) for anemia services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Ostrovsky receive payments from pharmaceutical companies?
Yes. Dr. Ostrovsky received a total of $8,921 from 77 companies across 441 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Ostrovsky's costs compare to other hematology & oncology specialists in Langhorne?
Dr. Ostrovsky's average Medicare payment per service is $9. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Ostrovsky) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Langhorne
Browse hematology & oncology specialists in Langhorne ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in PA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in PA
Which PA hematology & oncology specialists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology